You searched for ""

Boucher & Muir Pty Ltd (BNM), and ADVANZ PHARMA company, is an innovative pharmaceutical company delivering sustainable value across our product to customers in Australia, New Zealand and the South Pacific Island. BNM commenced business in 1957, a family owned and operated company. As an ADVANZ PHARMA company, BNM continues to espouse strong family…

The success of any company is driven by its people, and ADVANZ PHARMA is no different. Our teams are made up of people from all walks of life and backgrounds. We thrive in an environment where uniqueness is celebrated, but we are all united by the same passion, to purpose to improve patients’ lives by providing and enhancing the specialty, hospital, and…

Zavesca® (miglustat) is sold in over 40 markets across APAC, EMEA, Latin America and North America.*This acquisition further strengthens ADVANZ PHARMA’s global specialty brands portfolio and focus on rare disease. London, UK – 13/10/2025: - ADVANZ PHARMA Holdco Limited (“ADVANZ PHARMA” or “the Company”), a UK headquartered global pharmaceutical company…

LONDON, UK and REYKJAVIK, ICELAND (OCTOBER 6, 2025) — Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe and Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar…

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programs The agreement includes proposed biosimilars to Ilaris® (canakinumab), Kesimpta® (ofatumumab) and an additional early-stage undisclosed biosimilar candidate REYKJAVIK, ICELAND and LONDON, UK (May 28, 2025)…

London, UK – [15/05/2025] – ADVANZ PHARMA Holdco Limited (“ADVANZ PHARMA” or “the Company”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines across Europe, Canada, and Australia, today announced the expansion of its existing partnership with PHARMATHEN, a leading pharmaceutical…

REYKJAVIK, ICELAND and LONDON, UK (November 04, 2024) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and ADVANZ PHARMA, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today…

ADVANZ PHARMA releases its 2023-2024 ESG report reinforcing its commitment to sustainability.The report is structured across our three strategic ESG pillars: focusing on patients’ needs; ensuring sustainable and responsible operations and growth; and developing our people. London, UK – 04/10/2024: - ADVANZ PHARMA Holdco Limited ("ADVANZ PHARMA" or "the…

London, UK and Pune, INDIA – 27/08/2024: - ADVANZ PHARMA Holdco Limited (“ADVANZ PHARMA” or “the Company”), a UK headquartered global pharmaceutical company with a strategic focus on speciality, hospital and rare disease medicines in Europe, Canada, and Australia and Enzene Biosciences, a biopharmaceutical company specialising in the development and…

European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) The approvals process is anticipated to be completed in the third quarter of 2025 REYKJAVIK, ICELAND and LONDON, UK (August 15, 2024) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and…

ADVANZ PHARMA secures rights to commercialize Alvotech’s biosimilar candidate for Eylea® in EuropeADVANZ PHARMA will leverage its existing specialty and hospital capabilities in Europe to ensure successful market registration, commercialization, and patient access REYKJAVIK, ICELAND and LONDON, UK (June 18, 2024) — Alvotech (NASDAQ: ALVO), a global biotech…

The European Commission (EC) granted marketing authorisation for EXBLIFEP®Developed by Allecra, EXBLIFEP® will be marketed in the European Union, the United Kingdom, Switzerland, and Norway by ADVANZ PHARMA under a license and supply agreement closed with Allecra in 2022ADVANZ PHARMA is committed to improving patients’ lives by providing potent therapeutic…

The European Commission (EC) granted marketing authorisation for EXBLIFEP®Developed by Allecra, EXBLIFEP® will be marketed in the European Union, the United Kingdom, Switzerland, and Norway by ADVANZ PHARMA under a license and supply agreement closed with Allecra in 2022ADVANZ PHARMA is committed to improving patients’ lives by providing potent therapeutic…

EXBLIFEP® demonstrated in a phase III clinical trial significant superiority in the primary composite endpoint of clinical cure and microbiological eradication over piperacillin/tazobactam in patients with complicated urinary tract infections caused by gram negative bacteriaThe antibiotic drug was originally developed by Allecra Therapeutics up to Phase…

Androcur® (cyproterone acetate) is sold in more than 60 markets across Europe, Canada, APAC, MENA, and Latin AmericaThe acquisition leverages ADVANZ’s commercial and medical footprint in Europe, as well as its global distribution partner networkThe acquisition further strengthens ADVANZ’s global specialty brands portfolio London, UK – 07/11/2023: - ADVANZ…

ADVANZ PHARMA acquires exclusive rights to register and commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in the European Economic Area, the UK, Switzerland, Canada, Australia, and New ZealandDimerix to receive up to €138.5 million in upfront and milestone payments, plus royalties, comprising of;€6.5 million upfront…

London, UK – Monday 04 September, 2023: ADVANZ PHARMA Corp. Limited (“ADVANZ” or “the Company”), a UK headquartered global pharmaceutical company with a strategic focus on speciality, hospital, and rare disease medicines in Europe, is pleased to announce that we have signed an exclusive licensing and supply agreement with GP Pharm for a peptide specialty…

ADVANZ PHARMA releases its 2022-2023 ESG report highlighting its sustained progress on environmental, social, and governance topics.The report is structured across the three key pillars that are closely linked with the Company’s strategic priorities: focusing on patients’ needs; ensuring sustainable and responsible operations and growth; and developing our…

Advanz Pharma secures exclusive rights from Alvotech to commercialize five proposed biosimilars in Europe The agreement includes proposed biosimilars to Simponi® (golimumab), Entyvio® (vedolizumab) and three additional early-stage undisclosed biosimilar candidates Advanz Pharma will leverage its existing specialty and hospital capabilities in Europe to…

ADVANZ PHARMA secures exclusive rights to register and commercialise AT-007, a Phase 3 development compound for the treatment of several rare neurological diseases, including Galactosemia and SORD Deficiency, in the European Economic Area, the UK, and SwitzerlandADVANZ PHARMA will leverage its existing specialty, hospital, and rare disease expertise and…

ADVANZ PHARMA completes the acquisition of a hospital anti-infective portfolio from Sanofi, including the brands Azactam™, Cefotax™, Claforan™, Colimycin™, Oroken™, Rulid™, Suprax™ and Wintriaxone™.The acquisition further strengthens ADVANZ PHARMA’s specialty and hospital business in Europe and internationally and builds on its existing anti-infectives…

ADVANZ PHARMA to receive exclusive rights to commercialize D-PLEX100 for the prevention of surgical site infections in abdominal and cardiac surgeries in Europe, leveraging its specialty and hospital footprint PolyPid to potentially receive over $110 million in upfront and milestone payments LONDON, July [XX], 2022 /CNW/ - ADVANZ PHARMA Corp. Limited…

LONDON, [July 01], 2022 /CNW/ - ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA" or "the Company"), a UK-headquartered pharmaceutical company with a strategic focus on specialty and hospital pharmaceuticals in Europe, today announced that it has successfully completed the acquisition of the majority of Intercept’s subsidiaries and operations in Europe, Canada,…

Acquisition to strengthen ADVANZ PHARMA’s position as a partner of choice for commercialisation of specialty and hospital pharmaceuticals in EuropeAgreement includes ex-U.S. rights to commercialise orphan drug Ocaliva® for PBC, a progressive autoimmune disease affecting the liver, and the acquisition of the majority of Intercept’s subsidiaries and…

London, April 1, 2022: In accordance with previous announced information, ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA"), a pharmaceutical company with a strategic focus on specialty pharmaceuticals and specialty & hospital generics in Europe, today welcomes Steffen Wagner as its new CEO. Steffen joins from STADA, where he was a member of the Global…

Bringing quality medicines to patients is always the ultimate aim for companies within the pharmaceutical industry; however, the route and complexities in arriving at this point can sometimes be underestimated or understated, especially within the off-patent sector. There are a huge number of factors at play within this process, from the development of…

NOT FOR PUBLICATION IN THE UNITED STATESCidron Aida Finco S.à r.l. Successful pricing of €175.0 million 5% Senior Secured Notes due 2028JANUARY 19,2022. 16:00 GMT. Cidron Aida Finco S.à r.l. (the “Issuer”) today announced the successful pricing of its offering (the “Notes Offering”) of €175.0 million in aggregate principal amount of euro-denominated 5%…

NOT FOR PUBLICATION IN THE UNITED STATESCidron Aida Finco S.à r.l. Proposed Offering of €150 million 5% Senior Secured Notes due 2028JANUARY 17, 2022. 09:00 GMT. Cidron Aida Finco S.à r.l. (the “Issuer”) today announced an intention to offer (the “Offering”), subject to market conditions, €150.0 million in aggregate principal amount of euro-denominated 5%…

Allecra Therapeutics and ADVANZ PHARMA Sign Exclusive License and Supply Agreement for Allecra’s Antibiotic Cefepime/enmetazobactam in Europe Allecra receives upfront, development and commercial milestone payments, in addition to double-digit royaltiesADVANZ gains commercial rights for cefepime/enmetazobactam in the European Union, the United Kingdom,…

LONDON, December 9, 2021 - ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA" or "the Company"), a specialty pharmaceutical company committed to improving the lives of patients by enhancing the critical medicines they depend on, today launched its inaugural Environmental, Social & Governance (ESG) report. Key achievements highlighted in the report include: We…

Dr. Steffen Wagner appointed as new Chief Executive Officer and Andreas Stickler as new Chief Financial Officer LONDON, Nov. 18, 2021 /CNW/ - ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA" or "the Company"), a specialty pharmaceutical company with a strategic focus on complex medicines in Europe, today announced several changes in senior leadership roles as…

Norway, 11 November 2021 - ADVANZ PHARMA, a specialty pharmaceutical company with a strategic focus on complex medicines in Europe, has today announced the launch of MYRELEZ® (lanreotide) in Norway, the first generic lanreotide for the treatment of acromegaly, grade 1 and a subset of grade 2 gastroenteropancreatic neuroendocrine tumours and symptoms…

Patient safety forms the essential foundation of any healthcare system. While the introduction of innovative treatments, technologies and care models have shown great potential in transforming outcomes, they also pose new questions for monitoring and keeping patients safe, so much so that patient safety is now being recognised as a growing public health…

Bielefeld, Germany, 15 July 2021 - ADVANZ PHARMA, a specialty pharmaceutical company with a strategic focus on complex medicines in Europe, has today announced the launch of MYTOLAC® (lanreotide) in Germany, the first generic lanreotide for the treatment of acromegaly, grade 1 and a subset of grade 2 gastroenteropancreatic neuroendocrine tumours and…

Complete gender equality among employees is an aspiration for many companies, however, despite decades of progressive efforts, there is still a great deal of work to be done. At ADVANZ PHARMA, creating a gender equal working environment is a priority. We are committed to championing and empowering female employees and ensuring equal treatment and access to…

LONDON, UK, June 11, 2021: ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA" or "the Company"), a specialty pharmaceutical company with a strategic focus on complex medicines in Europe, is proud to announce that Kit Britten, VP for UK & Ireland Commercial, has been elected as chair of the British Generic Manufacturers Association (BGMA)’s Economic &…

ADVANZ PHARMA’s Global Director of Commercial Excellence David Johnson outlines the company’s investment in its omnichannel excellence programme and commitment to employees through new ways of working. A rapid increase in the use of digital channels in recent years has meant healthcare professionals (HCPs) are consuming and communicating information in a…

Chief Corporate Development Officer, Guy Clark shares his thoughts on ADVANZ PHARMA’s growth and investment strategy and how ADVANZ positions itself as the ‘go-to’ partner for M&A. “Growth” is a word we tend to associate with the expansion of a company’s capital or assets organically over a prolonged period of time. However successful growth within the…

Eve-Anadel Coronado is a vibrant and valued member of the ADVANZ Women’s Network (AWN). The AWN provides a space for gender issues and equality to be discussed without judgement. A space where each member has a voice, where smart ideas are shared, and tangible solutions are offered by women who can relate to each other’s daily personal and professional…

On Rare Disease Day 2021, our Chief Medical Officer, Nick Warwick, shares his thoughts on what this means to him and of the importance of not overlooking patient needs.The past year has been a time for true reflection and readjustment for many of us. At ADVANZ PHARMA, we have made a shift in our strategic compass to focus more on enriching our portfolio…

Agnès Bassage joined the ADVANZ Women’s Network (AWN) when it was established in 2018. She has been integral to the development of the platform designed to support and empower our female workforce. As Head of HR for our Europe, United Kingdom & North America business, Agnès is right in her element. ADVANZ PHARMA strives to achieve a high level of…

Tim Churchill is Director of Global Quality at ADVANZ PHARMA, based in our London office. Last year, Tim became the first male member of the ADVANZ Women’s Network (AWN), a decision taken by the network in order to bring a male perspective into discussions around gender equality. For Tim, AWN membership gave him the chance to be directly involved in working…

Our CEO, Graeme Duncan, shares his perspective on the changes the pharmaceutical industry has faced in 2020 and the trajectory of growth that ADVANZ PHARMA is pursuing into 2021 and beyond. Reflection is a word which, at its simplest, is about careful consideration and thought. With the end of 2020 on the imminent horizon, there is no time like the present…

Preeti Naik is based in our Mumbai office and brings significant expertise to the organisation with over 15 years of experience in Talent Management, Learning & Development and Performance Management. With a passion for Human Resources, Preeti is a valuable team member of the ADVANZ Women’s Network (AWN). As someone with an ardent interest in personal…

Our Chief Commercial Officer, Strategic Growth Unit, Paul Burden, provides his perspective on how ADVANZ PHARMA has overcome the challenges presented by the pandemic in supplying critical medicines in the UK, as well as the company’s commitment to growth in an everchanging environment. If we look back on the last six months, when it became clear that the…

Navigating lockdown as a new recruit at ADVANZ PHARMAOne of the newest recruits at ADVANZ PHARMA is Maciej Piwowarski, who joined our Business Development Team in London last month. He's not had the most traditional of starts, having had to work from home much like the rest of the team, as part of Government covid19 measures across Europe.Two months on,…

Boucher & Muir Pty Ltd (BNM), and ADVANZ PHARMA company, is an innovative pharmaceutical company delivering sustainable value across our product to customers in Australia, New Zealand and the South Pacific Island. BNM commenced business in 1957, a family owned and operated company. As an ADVANZ PHARMA company, BNM continues to espouse strong family…

Lorem

Lorem

The success of any company is driven by its people, and ADVANZ PHARMA is no different. Our teams are made up of people from all walks of life and backgrounds. We thrive in an environment where uniqueness is celebrated, but we are all united by the same passion, to purpose to improve patients’ lives by providing and enhancing the specialty, hospital, and…

Recent incidents have occurred involving person(s) falsely claiming to recruit on behalf of ADVANZ PHARMA. Please note that ADVANZ PHARMA or its group/subsidiary companies does not (nor do any of the organizations that recruit on our behalf) permit any unauthorized recruitment and in the process do not seek or provide money or payments. These communications…

Last updated: 01 Aug 2023 AS USED HEREIN, THE TERMS “YOU” AND “USER” SHALL MEAN ANY VISITOR TO THE WEBSITE. PLEASE READ THESE TERMS AND CONDITIONS CAREFULLY. This page sets out the terms and conditions of use ("Terms") which apply to Your use of www.bnm.advanzpharma.com and all other websites ("Website") operated by companies in the Advanz Pharma group.…

MISSISSAUGA, ON, Sept. 12, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR) issued a further announcement today, at the request of the Investment Industry Regulatory Organization of Canada (IIROC) and further to the Company's press release issued on September 11, 2018. Concordia's US$586.5 million private placement (the…

MISSISSAUGA, ON, Sept. 11, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today at the request of market regulators announced that as part of the Company's recently completed and previously…

MISSISSAUGA, ON, Sept. 6, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced the completion of the recapitalization transaction (the "Recapitalization Transaction") described in the…

- Also Announces Executive Leadership Transition - Second quarter 2018 revenue of approximately $139 millionSecond quarter 2018 GAAP net loss of $180 millionSecond quarter 2018 Adjusted EBITDA1 of approximately $67 millionGenerated cash flow from operations of approximately $84 million in the first six months of 2018 and concluded the second quarter of 2018…

Company also provides anticipated timing update for closing of its Recapitalization Transaction MISSISSAUGA, ON, July 25, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced it intends…

Concordia previously announced delisting notice on May 31, 2018 MISSISSAUGA, ON, July 19, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that as a result of the Company's decision…

OAKVILLE, ON, June 26, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that in connection with the previously announced recapitalization transaction (the "Recapitalization…

OAKVILLE, ON, June 19, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR) today announced that at the meetings (the "Debtholders' Meetings") of holders of certain secured debt of Concordia (the "Secured Debtholders") and holders of certain unsecured debt of Concordia (the "Unsecured Debtholders") and at the annual and…

OAKVILLE, ON, June 18, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR) announced today that, in connection with the previously announced proposed recapitalization transaction (the "Recapitalization Transaction") described in the Company's management information circular dated May 15, 2018 (the "Circular") and to be…

OAKVILLE, ON, June 7, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, announced today that the Company's previously announced recapitalization transaction (the "Recapitalization…

OAKVILLE, ON, May 28, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that Jordan Kupinsky, Non-Executive Chairman of the Board of Directors of Concordia (the…

OAKVILLE, ON, May 7, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced it intends to release its first quarter 2018 financial results before market open on Tuesday, May…

First quarter 2018 revenue of $152 million First quarter 2018 GAAP net loss of $56 millionFirst quarter 2018 adjusted EBITDA1 of $72 millionGenerated cash flow from operations of $51 million in the first quarter of 2018 and concluded the quarter with a cash balance of $344 million On May 2, 2018, announced the execution of a support agreement with…

OAKVILLE, ON, Feb. 15, 2018 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that the UK Competition and Markets Authority (CMA) has notified the Company that it is closing…

OAKVILLE, ON, Dec. 15, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that at the request of the Investment Industry Regulatory Organization of Canada ("IIROC"), the…

- Decisions on two other Concordia medications deferred OAKVILLE, ON, Nov. 21, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today commented on the issuance by the UK Competition…

OAKVILLE, ON, Nov. 1, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced it intends to release its third quarter 2017 financial results before market open on Tuesday,…

Concordia is seeking to reduce its existing secured and unsecured debt obligations by more than $2 billion, while significantly reducing its annual interest expense (the "Proposed Recapitalization Transaction")Canada Business Corporations Act (the "CBCA") is a Canadian corporate statute allowing Canadian corporations to restructure certain debt obligations.…

Company intends to operate its business as usual while continuing to honour its obligations to employees, suppliers and customersOAKVILLE, ON, Oct. 16, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty,…

OAKVILLE, ON, Oct. 11, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that the UK Competition and Markets Authority (CMA) is investigating new issues in relation to…

OAKVILLE, ON, Sept. 6, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced the details of DELIVER, its long-term growth strategy. "At its essence, the DELIVER strategy will focus…

OAKVILLE, ON, Aug. 30, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced it intends to disclose the details of DELIVER, its long-term growth strategy, on Wednesday, September 6, 2017at…

OAKVILLE, ON, July 28, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced it intends to release its second quarter 2017 financial results before market open on Friday, August 11, 2017. The…

OAKVILLE, ON, June 21, 2017 /CNW/ - Concordia International Corp. (the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced an update on the development of its long-term growth strategy. Further to previous communications, the Company's development of a…

OAKVILLE, ON, June 13, 2017 /CNW/ - Concordia International Corp. (the "Company") (NASDAQ: CXRX) (TSX: CXR) - together with its subsidiaries ("Concordia"), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced that RedHill Biopharma Ltd. (RedHill) (NASDAQ: RDHL) (TASE: RDHL), a specialty…

OAKVILLE, ON, June 9, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") held on June 9,…

OAKVILLE, ON, May 31, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced that the UK Competition and Markets Authority (CMA) has notified the Company that it intends to continue with its…

Itzhak Krinsky and Frank Perier, Jr. bring extensive pharmaceutical experience to the Board OAKVILLE, ON, May 4, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR) (NASDAQ: CXRX), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced that Itzhak Krinsky,…

OAKVILLE, ON, May 2, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced it intends to release its first quarter 2017 financial results before market open on Wednesday, May 10, 2017. The…

- Company to Conduct First Quarter Earnings Call on May 10, 2017 in the Ordinary Course OAKVILLE, ON, April 26, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (TSX: CXR) (NASDAQ: CXRX), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced that David Price has been…

OAKVILLE, ON, March 9, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced it intends to release its fourth quarter and year-end 2016 financial results before market open on Wednesday,…

OAKVILLE, ON, March 3, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today commented on the issuance by the UK Competition and Markets Authority (CMA) of a Statement of Objections to Actavis UK…

OAKVILLE, ON, Feb. 1, 2017 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced that it has paid the second and final installment of its earn-out to Cinven1 relating to…

Performance-based arrangement predicated on sales exceeding predetermined levelsCo-promotional agreement is consistent with Concordia's strategic focus on operational excellenceOAKVILLE, ON, Jan. 3, 2017 /CNW/ - Concordia International Corp. (the "Company") (NASDAQ: CXRX) (TSX: CXR) - together with its subsidiaries ("Concordia") - an international specialty…

OAKVILLE, ON, Dec. 28, 2016 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced that effective January 1, 2017, John Beighton will retire from his current role as President of…

OAKVILLE, ON, Dec. 19, 2016 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced that the Company has paid the first installment of its earn-out to Cinven1 relating to…

Allan Oberman named Chief Executive OfficerJordan Kupinsky appointed Chairman of the BoardOAKVILLE, ON, Nov. 2, 2016 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR) today announced that its Board of Directors has appointed Allan Oberman as its new Chief Executive Officer and selected Jordan Kupinsky as Chairman…

OAKVILLE, ON, Nov. 1, 2016 /CNW/ - Concordia International Corp. (the "Company") (NASDAQ: CXRX) (TSX: CXR) - together with its subsidiaries ("Concordia") - an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced that it has entered into an additional cross currency swap…

TORONTO, Oct. 26, 2016 /CNW/ - Concordia International Corp. ("Concordia" or "the Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced it intends to release its third quarter 2016 financial results before market open on Monday, November…

OAKVILLE, ON, Oct. 25, 2016 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced that the UK Competition and Markets Authority (CMA) is investigating various issues in relation…

OAKVILLE, ON, Oct. 21, 2016 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR) today announced that Mark L. Thompsonwill step down as Chief Executive Officer of the Company following the appointment of a successor. "Mark was our founder and successfully built Concordia into an international specialty…

OAKVILLE, ON, Oct. 13, 2016 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced the closing of its previously disclosed offering (the "Offering") of 5 ½ year Senior Secured…

OAKVILLE, ON, Oct. 6, 2016 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced the pricing of its previously disclosed offering (the "Offering") of 5 ½ year Senior Secured First…

OAKVILLE, ON, Oct. 5, 2016 /CNW/ - Concordia International Corp. (Concordia or the Company) (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today announced its intention to commence an offering (the "Offering"), subject to market conditions and other factors, of up to $350…

OAKVILLE, ON, Oct. 3, 2016 /CNW/ - Concordia International Corp. (the "Company") (NASDAQ: CXRX) (TSX: CXR) – together with its subsidiaries ("Concordia") - an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today announced that it has exercised an option to defer half of the anticipated £144 million earn-out…

OAKVILLE, ON, Aug. 22, 2016 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, stated that Concordia's Chairman and Chief Executive Officer Mark Thompson was notified earlier today of the sale of 505,000 of his…

OAKVILLE, ON, Aug. 15, 2016 /CNW/ - Concordia International Corp. (the "Company") (NASDAQ: CXRX) (TSX: CXR) - together with its subsidiaries ("Concordia") - an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today announced that it has entered into a cross currency swap agreement (the "Swap Agreement"). As…

OAKVILLE, ON, Aug. 3, 2016 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today confirmed that its review of strategic alternatives is ongoing and provided an update on its business. Concordia disclosed on…

TORONTO, July 19, 2016 /CNW/ - Concordia International Corp. ("Concordia" or "the Company") (NASDAQ: CXRX) (TSX: CXR) today announced it intends to release its second quarter 2016 financial results before market open on Friday, August 12, 2016. The Company will subsequently hold a conference call that same day, Friday, August 12, 2016, at 8:30 a.m. ET…

OAKVILLE, ON, July 13, 2016 /CNW/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today provided an update to its June 28, 2016 press release relating to the potential impact on the Company's financial operations of…

OAKVILLE, ON, June 2, 2016 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, confirmed today that its review of strategic alternatives is ongoing. Concordia disclosed on April 21, 2016, that it formed a special…

OAKVILLE, ON, April 29, 2016 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (TSX: CXR) (NASDAQ: CXRX), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, announced today the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting") held on April 29, 2016, in…

TORONTO, April 19, 2016 /CNW/ - Concordia Healthcare Corp. ("Concordia" or "the Company") NASDAQ: CXRX) (TSX: CXR) today announced it intends to release its first quarter 2016 financial results before market open on Friday, May 13, 2016. The Company will subsequently hold a conference call that same day, Friday, May 13, 2016, at 8:30 a.m. ET hosted by Mr.…

OAKVILLE, ON, March 29, 2016 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, today announced that it is providing information to correct inaccuracies and misstatements that appeared in a recent media report…

OAKVILLE, ON, Feb. 16, 2016 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, announced today that Edward Borkowski, currently a member of Concordia's Board of Directors, will join the organization as Executive Vice…

OAKVILLE, ON, Jan. 15, 2016 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, announced today that its Chairman and CEO Mark Thompson is scheduled to deliver a corporate presentation at the CIBC 19th Annual Whistler…

OAKVILLE, ON, Jan. 11, 2016 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, announced today a number of corporate developments. Change of CFO at Concordia's subsidiary, Amdipharm Mercury Limited (AMCo) Adeel Ahmad,…

OAKVILLE, ON, Dec. 15, 2015 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs, announced today that it intends to pay down US$11.25 million of its US$45 million senior unsecured bridge loan, and US$33.75 million of…

- Launch demonstrates organic growth potential of newly acquired AMCo platform - OAKVILLE, ON, Nov. 23, 2015 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR) announced today that Amdipharm Mercury Limited ("AMCo") has launched Nefopam, a generic version of Accupan. Nefopam is a non-narcotic painkiller for the…

TORONTO, Oct. 30, 2015 /CNW/ - Concordia Healthcare Corp. ("Concordia" or "the Company") (NASDAQ: CXRX) (TSX: CXR) today announced it will release its third quarter 2015 financial results after market close on Thursday, November 12, 2015. The Company will subsequently hold a conference call on Friday, November 13, 2015, at 8:30 a.m. ET hosted by Mr. Mark…

OAKVILLE, ON, Oct. 30, 2015 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR) announced today that its founder, Chairman and Chief Executive Officer Mark Thompson will appear on Business News Network program Weekly with Andrew McCreath today at 5:30 pm ET to discuss the Company's overall business and preliminary…

OAKVILLE, ON, Oct. 26, 2015 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR) announced today its preliminary guidance for 2016. For the full 2016 fiscal year, Concordia estimates1: Revenues of US$1,020 million to US$1,060 millionAdjusted EBITDA2 of US $610 million to US$640 millionAdjusted net income2 of US$330…

Continued strong free cash flowBroadly diversified portfolio with more than 200 products sold in over 100 countries, and approximately 60 per cent of revenues expected to be generated outside the U.S. post-acquisitionPipeline of approximately 60 new launches expected to drive mid-teen organic revenue growth in markets outside the U.S. driven primarily by…

OAKVILLE, ON, Oct. 21, 2015 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR) announced today that its founder, Chairman and Chief Executive Officer Mark Thompson will appear on BNN's The Business News with Michael Hainsworth today at 12:20 pm ET to discuss the closing of the acquisition of Amdipharm Mercury Limited…

OAKVILLE, ON, Oct. 20, 2015 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR) announced today the pricing of 9.5% Senior Notes due 2022 (the "Notes"). The principal amount of the Notes is US$790 million and the Notes were priced at an issue price of 100.0% of their face amount to yield 9.5%. The Notes will be senior…

OAKVILLE, ON, Oct. 20, 2015 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR) announced today that its term loans of approximately US$ 1,865 millioni (US$1.1 billion and £500 million) (the "Term Loans"), being raised in connection with the financing of its acquisition of Amdipharm Mercury Limited ("AMCo"), have been…

OAKVILLE, ON, Oct. 15, 2015 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR) announced today the finalization of the structure of its financing for the acquisition of Amdipharm Mercury Limited ("AMCo") and its post acquisition capital structure. The Company also announced today it entered into an amended and…

OAKVILLE, ON, Oct. 14, 2015 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR) announced today that its Board of Directors has adopted an advance notice by-law (the "By-law"), establishing a framework for advance notice of nominations of directors by shareholders of Concordia. The By-law is similar to the advance…

OAKVILLE, ON, Oct. 9, 2015 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR) is pleased to provide an update on its acquisition of Amdipharm Mercury Limited ("AMCo"). As previously announced, the Company has fully committed debt financing of approximately US$2.8 billion from certain financial institutions to fund…

OAKVILLE, ON, Sept. 30, 2015 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR) today announced that, further to its September 24, 2015 press release, it has completed its underwritten public offering (the "Offering") of 8,000,000 common shares of Concordia for aggregate gross proceeds of US$520 million. The Offering…

TORONTO, Sept. 21, 2015 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR) today announced that it has filed a preliminary prospectus supplement (the "Preliminary Supplement") to the short form base shelf prospectus dated July 16, 2015, with the securities regulatory authorities in each of the provinces of Canada and…

TORONTO, July 29, 2015 /CNW/ - Concordia Healthcare Corp. ("Concordia" or "the Company") (NASDAQ: CXRX) (TSX: CXR), today announced it will release its second quarter 2015 financial results after market close on Thursday, August 13, 2015. The Company will subsequently hold a conference call on Friday, August 14, 2015, at 8:30 a.m. ET hosted by Mr. Mark…

TORONTO, July 10, 2015 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (TSX: CXR) (NASDAQ: CXRX), a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs, today announced that it has filed a preliminary short form base shelf prospectus (the "Prospectus") with the securities regulatory authorities in each of…

TORONTO, June 25, 2015 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (TSX: CXR) (OTCQX: CHEHF), announced today that all of the nominees listed in the Company's Management Information Circular, dated May 25, 2015, for the 2015 Annual General Meeting of shareholders held on June 25, 2015, in Toronto, Ontario, (the "Meeting") were elected…

TORONTO, May 25, 2015 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs, today announced several key changes to the Company's board of directors (the "Board") and management team. Board of Directors The Company announced today…

Photodynamic therapy with PHOTOFRIN® being studied in range of cancers OAKVILLE, ON, May 7, 2015 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today provided a clinical update…

ORONTO, April 24, 2015 /CNW/ - Concordia Healthcare Corp. ("Concordia" or "the Company") (TSX: CXR) (OTCQX: CHEHF), today announced it will release its first quarter 2015 financial results after market close on Thursday, May 14, 2015. The Company will subsequently hold a conference call on Friday, May 15, 2015, at 8:30 a.m. ET hosted by Mr. Mark Thompson,…

TORONTO, April, 21, 2015 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs, today announced that it has completed the previously announced acquisition by the Company of 18 products, being comprised of 12 branded products and…

/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES./ TORONTO, April 8, 2015 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (TSX: CXR), is pleased to announce that it has closed its previously announced short form prospectus…

TORONTO, April 6, 2015 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (TSX:CXR)(OTCQX:CHEHF) announced today that it intends, subject to market and other conditions, to offer US$610,000,000 aggregate principal amount of its Senior Notes due 2023 (the "Notes") to qualified institutional buyers pursuant to Rule 144A under the Securities Act…

TORONTO, March 16, 2015 /CNW/ - Concordia Healthcare Corp. ("Concordia" or "the Company") (TSX: CXR) (OTCQX: CHEHF), today announced it will release its fourth quarter and year-end 2014 financial results after market close on Thursday, March 19, 2015. The Company will subsequently hold a conference call on Friday, March 20, 2015, at 8:30 a.m. ET hosted by…

/Not for release in the United States./ Creates Diversified, Scaled Specialty Pharmaceutical Company and Expands Concordia's Platform for Future GrowthAddition of 18 Branded and Authorized Generic Products Provides Revenue Diversification and Enhances the Legacy Portfolio Margin ProfileExcellent Fit with Concordia's Existing Operations and Product…

TORONTO, Feb. 12, 2015 /CNW/ - Concordia Healthcare Corp., ("Concordia") (TSX: CXR) (OTCQX: CHEHF), today provided a corporate update on various matters, including its Phase 3 clinical trial to treat a rare form of bile duct cancer. Concordia enrolls first Korean patient in Phase 3 bile duct cancer trial Concordia announced today it has enrolled its first…

TORONTO, Sept. 24, 2015 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR) today announced the size and pricing of its underwritten public offering (the "Offering") of 8,000,000 common shares of Concordia at a price of US$65.00 per common share (the "Offering Price"). The gross proceeds from the Offering are expected…

TORONTO, Dec. 22, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that Paul Manning has resigned from the Board of Directors of the Company, effective January…

TORONTO, Nov. 28, 2014 /CNW/ - Concordia Healthcare Corp., ("Concordia") (TSX: CXR) (OTCQX: CHEHF), announced today a clinical trial and corporate update, including the status of patient enrollment in its Phase 3 clinical trial to treat a rare form of bile duct cancer, and the entering into of an exclusive trademark license and product distribution…

TORONTO, Nov. 13, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced its financial and operational results for the three and nine months ended September 30,…

TORONTO, Oct. 23, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia" or "the Company") (TSX: CXR) (OTCQX: CHEHF), today announced it will release its third quarter 2014 financial results after market close on Thursday, November 13, 2014. The Company will subsequently hold a conference call on Friday, November 14, 2014, at 8:30 a.m. ET hosted by Mr. Mark…

TORONTO, Sept. 30, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that its subsidiary, Concordia Pharmaceuticals Inc. ("CPI"), has completed the previously…

TORONTO, Sept. 3, 2014 /CNW/ - Concordia Healthcare Corp. (Concordia or the Company) (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that its subsidiary, Concordia Pharmaceuticals Inc., has entered into a definitive agreement…

TORONTO AND CHICAGO, Sept. 2, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia") (TSX:CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that its subsidiary, Pinnacle Biologics, Inc. ("Pinnacle"), a biopharmaceutical research and…

TORONTO, Aug. 13, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced its financial and operational results for the three and six months ended June 30, 2014. All…

TORONTO, ON and CHICAGO, IL, Aug. 11, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia") (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, announced today that its subsidiary Pinnacle Biologics, Inc., a biopharmaceutical research and…

Thomas Jefferson University Hospital is first site opened, more sites scheduled in August TORONTO AND CHICAGO, Aug. 5, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia") (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, and its subsidiary…

TORONTO, July 31, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia") (TSX: CXR) (OTCQX: CHEHF) today announced it will release its second quarter 2014 financial results after market close on Wednesday, August 13, 2014. The Company will subsequently hold a conference call on Thursday, August 14, 2014, at 8:30 a.m. ET hosted by Mr. Mark Thompson, President…

TORONTO, June 27, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia") (TSX: CXR) (OTCQX: CHEHF), today announced that all of the nominees listed in the Management Information Circular of Concordia, dated May 23, 2014, for the 2014 Annual and Special Meeting of Shareholders held on June 27, 2014, in Toronto, Ontario, (the "Meeting") were elected as…

TORONTO, June 12, 2014 /CNW/ - Concordia Healthcare Corp. (TSX: CXR) (OTCQX: CHEHF), today announced that Mark Thompson, Chief Executive Officer, will present at the 2014 Bloom Burton & Co. Healthcare Investor Conference in Toronto, Ontario. Concordia's presentation will take place on Wednesday, June 18, 2014, at 11:00 a.m. ET. Bloom Burton's third…

TORONTO, May 15, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced its financial and operational results for its first quarter, ended March 31, 2014. The…

TORONTO, May 15, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia" or the "Company") (TSX: CXR) (OTCQX: CHEHF), announced today that it has completed the previously announced acquisition of Donnatal®, an adjunctive therapy in the treatment of irritable bowel syndrome ("IBS") and acute enterocolitis, from a privately held specialty pharmaceutical company…

TORONTO, May 5, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia") (TSX: CXR) (OTCQX: CHEHF) today announced it will release its first quarter 2014 financial results on Thursday, May 15, 2014, before market open. The Company will subsequently hold a conference call on Thursday, May 15, 2014, at 8:30 a.m. ET hosted by Mr. Mark Thompson, President and…

Supplemental approval will expand PDT with Photofrin® treatments in specific lung and esophageal cancers TORONTO AND BANNOCKBURN, IL, March 26, 2014 /CNW/ - Concordia Healthcare Corp. (Concordia or the Company) (TSX:CXR) (OTCQX: CHEHF) announced today that its subsidiary Pinnacle Biologics, Inc. (Pinnacle), a biopharmaceutical research and development…

TORONTO, March 24, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia") (TSX: CXR) (OTCQX: CHEHF) today announced it will release its 2013 year-end financial results on Monday, March 31, 2014, before market open. The Company will subsequently hold a conference call on Monday, March 31, 2014, at 8:30 a.m. ET hosted by Mr.Mark Thompson, President and Chief…

/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TOUNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES./ TORONTO, March 11, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia") (TSX: CXR), is pleased to announce that it has closed its previously announced short form prospectus offering, on a…

Agreement represents continued movement forward in the development of a potential new treatment for rare cancers TORONTO and BANNOCKBURN, Ill., Jan. 13, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia" TSX:CXR) announced today that its subsidiary Pinnacle Biologics, Inc. ("Pinnacle"), a biopharmaceutical research and development company specializing in…

TSX: CXR TORONTO, Jan. 6, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia"), an integrated, specialty healthcare company focused on the acquisition of legacy pharmaceutical products, the acquisition and development of orphan drugs, and distribution of medical devices servicing the diabetic population announced today that it has entered into an Exclusive…

TSX: CXR TORONTO, Dec. 30, 2013 /CNW/ - Concordia Healthcare Corp., an integrated, specialty healthcare company focused on the acquisition of legacy pharmaceutical products, the acquisition and development of orphan drugs, and distribution of medical devices servicing the diabetic population announced today that it has filed a submission with Health Canada…